[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:ovarian-neoplasm":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":41,"states":42},"Ovarian Neoplasm",5,[7,15,22,29,35],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04641247","A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline\u002FTESARO-sponsored Niraparib Study",[11],"Phase 2","RECRUITING","2026-08-26T02:15:57.572488Z","2026-05-05T02:43:27.111224Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07213804","A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer",[19],"Phase 3","2026-08-26T02:17:27.435233Z","2026-07-05T05:32:16.660912Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT04895709","A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",[26],"Phase 1\u002FPhase 2","2026-08-26T02:19:00.742020Z","2026-06-16T05:54:07.907527Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT06566716","A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass",[],"2026-08-26T02:16:59.895916Z","2026-05-13T02:55:06.510715Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT01950572","Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma",[],"2026-08-26T02:18:59.761994Z","2026-07-05T05:32:16.769586Z",[],[43,47,50,53,56,59],{"state":44,"count":45,"slug":46},"Arizona",3,"arizona",{"state":48,"count":45,"slug":49},"California","california",{"state":51,"count":45,"slug":52},"Florida","florida",{"state":54,"count":45,"slug":55},"New York","new-york",{"state":57,"count":45,"slug":58},"Tennessee","tennessee",{"state":60,"count":45,"slug":61},"Texas","texas"]